Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study
Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan with an IND submission for
Read moreMind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan with an IND submission for
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to develop R(-)-MDMA for treating symptoms
Read moreEarlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced Thursday night its interim financial results for Q2 2021.
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of Phase 1 clinical trial on
Read moreEight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing
Read moreIt seems that after selling $24.7 million in company stock, JR Rahn is looking to step down from Mind Medicine
Read moreIt appears that uplisting to the Nasdaq is good for business. Or, at least for liquidity, as per insider action
Read moreMindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects of serotonergic hallucinogen mescaline have
Read moreMind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched Project Angie. The project is
Read more